Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal women

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 26, Issue 7, 2006, Pages 1660-1666

  Hemelaar, Majoie ^a   Rosing, Jan ^c   Kenemans, Peter ^a   Thomassen, M Christella L G D ^c   Braat, Didi D M ^b   Van Der Mooren, Marius J ^a,d  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

APC resistance; Hormone therapy; Intranasal; Menopause; Norethisterone; Venous thrombosis

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; D DIMER; ESTRADIOL PLUS NORETHISTERONE ACETATE; PROTEIN C; PROTEIN S; PROTHROMBIN; ESTRADIOL; NORETHISTERONE; PEPTIDE FRAGMENT; PROTHROMBIN FRAGMENT 1.2;

ABDOMINAL DISEASE; ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; HEMOSTASIS; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SENSITIVITY ANALYSIS; THROMBIN TIME; VAGINA BLEEDING; VAGINA CANDIDIASIS; VEIN THROMBOSIS; ACTIVATED PROTEIN C RESISTANCE; BLOOD; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG COMBINATION; ESTROGEN THERAPY; INTRANASAL DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ACTIVATED PROTEIN C RESISTANCE; ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ADULT; AGED; ANTITHROMBINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HEMOSTASIS; HUMANS; MIDDLE AGED; NORETHINDRONE; PEPTIDE FRAGMENTS; PROTEIN S; PROTHROMBIN; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 33745942586     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000224325.96659.53     Document Type: Article

References (36)

1. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996;348:977-980.
2. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc. 2002;288:321-333.
3. Scarabin PY, Oger E, Plu-Bureau. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003;362:428-432.
4. Perez GS, Garcia Rodriguez LA, Castellsague J, Duque OA. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ. 1997;314:796-800.
5. Høibraaten E, Abdelnoor M, Sandset PM. Hormone replacement therapy with estradiol and risk of venous thromboembolism - a population-based case-control study. Thromb Haemost. 1999;82:1218-1221.
6. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993;90:1004-1008.
7. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
8. Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993;342:1503-1506.
9. de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood. 1999;93:1271-1276.
10. Rosing J, Middeldorp S, Curvers J, Thomassen MC, Nicolaes GA, Meijers JC, Bouma BN, Büller HR, Prins MH, Tans G. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet. 1999;354:2036-2040.
11. Curvers J, Thomassen MC, Rimmer J, Hamulyak K, van der Meer J, Tans G, Preston FE, Rosing J. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test. Thromb Haemost. 2002;88:5-11.
12. Høibraaten E, Mowinckel MC, de Ronde H, Bertina RM, Sandset PM. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. Br J Haematol. 2001;115:415-420.
13. Post MS, Rosing J, van der Mooren MJ, Zweegman S, van Baal WM, Kenemans P, Stehouwer CD. Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy postmenopausal women. Br J Haematol. 2002;119:1017-1023.
14. Post MS, Thomassen MC, van der Mooren MJ, van Baal WM, Rosing J, Kenemans P, Stehouwer CD. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol. 2003;23:1116-1121.
15. Oger E, Alhenc-Gelas M, Lacut K, Blouch MT, Roudaut N, Kerlan V, Collet M, Abgrall JF, Aiach M, Scarabin PY, Mottier D. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol. 2003;23:1671-1676.
16. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet. 1999;353:1167-1173.
17. Cofrancesco E, Cortellaro M, Corradi A, Ravasi F, Bertocchi F. Coagulation activation markers in the prediction of venous thrombosis after elective hip surgery. Thromb Haemost. 1997;77:267-269.
18. Zoller B, Holm J, Svensson P, Dahlbäck B. Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency. Thromb Haemost. 1996;75:270-274.
19. Gouin-Thibault I, Arkam R, Nassiri S, de la TA, Conard J, Horellou MH, Elalamy I, Samama MM. Markers of activated coagulation in patients with factor V Leiden and/or G20210A prothrombin gene mutation. Thromb Res. 2002;107:7-11.
20. Andreescu AC, Cushman M, Rosendaal FR. D-dimer as a risk factor for deep vein thrombosis: the Leiden Thrombophilia Study. Thromb Haemost. 2002;87:47-51.
21. Cushman M, Folsom AR, Wang L, Aleksic N, Rosamond WD, Tracy RP, Heckbert SR. Fibrin fragment D-dimer and the risk of future venous thrombosis. Blood. 2003;101:1243-1248.
22. Cano A, van Baal WM. The mechanisms of thrombotic risk induced by hormone replacement therapy. Maturitas. 2001;40:17-38.
23. Scarabin PY, Alhenc-Gelas M, Plu-Bureau, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol. 1997;17:3071-3078.
24. Post MS, van der Mooren MJ, van Baal WM, Blankenstein MA, Merkus HM, Kroeks MV, Franke HR, Kenemans P, Stehouwer CD. Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebocontrolled study. Am J Obstet Gynecol. 2003;189:1221-1227.
25. Mattsson LA, Christiansen C, Colau JC, Palacios S, Kenemans P, Bergeron C, Chevallier O, Von Holst T, Gangar K. Clinical equivalence of intranasal and oral 17beta-estradiol for postmenopausal symptoms. Am J Obstet Gynecol. 2000;182:545-552.
26. Kenemans P, Genazzani AR, Palacios S, Schneider HP. Pulsed estrogen exposure selectively modulates tissue response: a hypothesis. Gynecol Endocrinol. 2004;18:159-164.
27. Rosing J, Tans G, Govers-Riemslag JW, Zwaal RF, Hemker HC. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem. 1980;255:274-283.
28. Nicolaes GA, Thomassen MC, van Oerle R, Hamulyak K, Hemker HC, Tans G, Rosing J. A prothrombinase-based assay for detection of resistance to activated protein C. Thromb Haemost. 1996;76:404-410.
29. Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, Vittinghoff E, Hulley S. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/Progestin Replacement Study. Ann Intern Med. 2000;132:689-696.
30. Devissaguet JP, Brion N, Lhote O, Deloffre P. Pulsed estrogen therapy: pharmacokinetics of intranasal 17-beta-estradiol (S21400) in postmenopausal women and comparison with oral and transdermal formulations. Eur J Drug Metab Pharmacokinet. 1999;24:265-271.
31. Høibraaten E, Qvigstad E, Andersen TO, Mowinckel MC, Sandset PM. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism - results from a randomized, double-blind, clinical trial. Thromb Haemost. 2001;85:775-781.
32. Salobir BG, Keber I, Vrabic L. A randomized, placebo-controlled trial of the effects of continuous combined hormone replacement therapy on coagulation and fibrinolytic systems in healthy postmenopausal women. Fertil Steril. 2002;78:1178-1183.
33. Sidelmann JJ, Jespersen J, Andersen LF, Skouby SO. Hormone replacement therapy and hypercoagulability. Results from the Prospective Collaborative Danish Climacteric Study. BJOG. 2003;110:541-547.
34. The Writing Group for the Estradiol Clotting Factors Study. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year, double-blind, placebo-controlled study. Thromb Haemost. 1996;75:476-480.
35. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, Virkamaki A, Hovatta O, Hamsten A, Taskinen MR, Yki-Jarvinen H. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost. 2001;85:619-625.
36. Stevenson JC, Oladipo A, Manassiev N, Whitehead MI, Guilford S, Proudler AJ. Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers. Br J Haematol. 2004;124:802-808.